NYSE:PBH - Prestige Consumer Healthcare Stock Price, Forecast & News

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare Inc (NYSE:PBH) announced its earnings results on Thursday, February, 6th. The company reported $0.81 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.75 by $0.06. The firm had revenue of $241.60 million for the quarter, compared to the consensus estimate of $240.34 million. Prestige Consumer Healthcare had a positive return on equity of 13.17% and a negative net margin of 3.57%. The firm's revenue for the quarter was up .1% on a year-over-year basis. During the same period in the previous year, the business earned $0.73 EPS. View Prestige Consumer Healthcare's Earnings History.

Prestige Consumer Healthcare is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Prestige Consumer Healthcare.

Prestige Consumer Healthcare issued an update on its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share (EPS) guidance of $2.85-2.87 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.82. The company issued revenue guidance of $947-957 million, compared to the consensus revenue estimate of $950.04 million.

4 equities research analysts have issued twelve-month price targets for Prestige Consumer Healthcare's stock. Their forecasts range from $84.00 to $106.00. On average, they expect Prestige Consumer Healthcare's share price to reach $95.67 in the next year. This suggests a possible upside of 141.5% from the stock's current price. View Analyst Price Targets for Prestige Consumer Healthcare.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Prestige Consumer Healthcare.

Headlines about PBH stock have trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Prestige Consumer Healthcare earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Prestige Consumer Healthcare.

Some companies that are related to Prestige Consumer Healthcare include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Avon Products (AVP), Inter Parfums (IPAR), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Medifast (MED), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Gilead Sciences (GILD), AbbVie (ABBV), Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH), Rigel Pharmaceuticals (RIGL), Johnson & Johnson (JNJ), Marathon Petroleum (MPC), Pfizer (PFE), AT&T (T) and Wells Fargo & Co (WFC).

Prestige Consumer Healthcare's stock is owned by many different of institutional and retail investors. Top institutional investors include Champlain Investment Partners LLC (4.73%), FMR LLC (3.79%), ArrowMark Colorado Holdings LLC (3.70%), State Street Corp (3.54%), Goldman Sachs Group Inc. (3.46%) and Acadian Asset Management LLC (2.85%). Company insiders that own Prestige Consumer Healthcare stock include Jean A Boyko, Paton Brett and Timothy Connors. View Institutional Ownership Trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Goldman Sachs Group Inc., Acadian Asset Management LLC, State of Tennessee Treasury Department, Prudential Financial Inc., Lapides Asset Management LLC, Oxford Asset Management LLP and Skyline Asset Management LP. View Insider Buying and Selling for Prestige Consumer Healthcare.

PBH stock was bought by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Wedge Capital Management L L P NC, Man Group plc, Peregrine Capital Management LLC, Massachusetts Financial Services Co. MA, Martingale Asset Management L P, Turtle Creek Asset Management Inc. and LSV Asset Management. View Insider Buying and Selling for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $39.61.

Prestige Consumer Healthcare has a market capitalization of $1.99 billion and generates $975.78 million in revenue each year. The company earns $-35,800,000.00 in net income (profit) each year or $2.78 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe.View Additional Information About Prestige Consumer Healthcare.

The official website for Prestige Consumer Healthcare is http://www.prestigebrands.com/.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]